Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;35(5):1341-5.
doi: 10.1007/s10067-016-3243-8. Epub 2016 Apr 6.

Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire)

Nibah Fatimah  1   2 , Babur Salim  3 , Amjad Nasim  3 , Kamran Hussain  3 , Harris Gul  3 , Sarah Niazi  3
Affiliations

Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire)

Nibah Fatimah et al. Clin Rheumatol. 2016 May.

Abstract

The objective of the study was to determine the frequency of methotrexate intolerance in rheumatoid arthritis (RA) patients by applying the methotrexate intolerance severity score (MISS) questionnaire and to see the effect of dose and concomitant use of other disease-modifying antirheumatic drugs (DMARDS) on methotrexate (MTX) intolerance. For the descriptive study, non-probability sampling was carried out in the Female Rheumatology Department of Fauji Foundation Hospital (FFH), Rawalpindi, Pakistan. One hundred and fifty diagnosed cases of RA using oral MTX were selected. The MISS questionnaire embodies five elements: abdominal pain, nausea, vomiting, fatigue and behavioural symptoms. The amplitude of each element was ranked from 0 to 3 being no complaint (0 points), mild (1 point), moderate (2 points) and severe (3 points). A cut-off score of 6 and above ascertained intolerance by the physicians. A total of 33.3 % of the subjects exhibited MTX intolerance according to the MISS questionnaire. Out of which, the most recurring symptom of all was behavioural with a value of 44 % whereas vomiting was least noticeable with a figure of 11 %. About 6.6 % of the women with intolerance were consuming DMARDs in conjunction with MTX. Those using the highest weekly dose of MTX (20 mg) had supreme intolerance with prevalence in 46.2 % of the patients. The frequency of intolerance decreased with a decrease in weekly dose to a minimum of 20 % with 7.5 mg of MTX. MTX intolerance has moderate prevalence in RA patients and if left undetected, the compliance to use of MTX as a first-line therapy will decrease. Methotrexate intolerance is directly proportional to the dose of MTX taken. Also, there is no upstroke seen in intolerance with the use of other disease-modifying agents.

Keywords: Concomitant DMARD therapy; Methotrexate; Methotrexate dose; Methotrexate intolerance severity score; Rheumatoid arthritis.

PubMed Disclaimer

References

    1. Arthritis Res. 2002;4 Suppl 3:S265-72 - PubMed
    1. Clin Exp Rheumatol. 2010 May-Jun;28(3 Suppl 59):S18-27 - PubMed
    1. Singapore Med J. 2009 Jul;50(7):686-92 - PubMed
    1. Rheum Dis Clin North Am. 2012 May;38(2):311-25 - PubMed
    1. Lancet. 2010 Sep 25;376(9746):1094-108 - PubMed

MeSH terms

LinkOut - more resources